Heron Therapeutics (HRTX) EBIT (QoQ) (2010 - 2026)
Powered by 
Analysis
Heron Therapeutics (HRTX) EBIT (QoQ) (2010 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 207.47 Bn | 193.48 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 178.76 Bn | 175.58 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 131.52 Bn | 123.67 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 81.91 Bn | 73.91 Bn | 3.93 Bn |
| 5 | Argenx Se | 61.10 Bn | 55.91 Bn | 1.37 Bn |
| 6 | Moderna | 53.44 Bn | 48.30 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.55 Bn | 30.24 Bn | 992.69 Mn |
| 8 | Biogen | 31.67 Bn | 30.39 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.63 Bn | 29.63 Bn | 1.16 Mn |
| 10 | Heron Therapeutics | 61.54 Mn | 18.87 Mn | 26.09 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 57.10% |
| Mar 31, 2026 | -12,639.47% |
| Dec 31, 2025 | 100.93% |
| Sep 30, 2025 | -150.03% |
| Jun 30, 2025 | -151.90% |
| Mar 31, 2025 | -24.42% |
| Dec 31, 2024 | 193.61% |
| Sep 30, 2024 | 30.83% |
| Jun 30, 2024 | -34.33% |
| Mar 31, 2024 | 53.05% |
| Dec 31, 2023 | 59.00% |
| Sep 30, 2023 | 41.21% |
| Jun 30, 2023 | -28.25% |
| Mar 31, 2023 | -62.43% |
| Dec 31, 2022 | 51.40% |
| Sep 30, 2022 | 15.39% |
| Jun 30, 2022 | 21.34% |
| Mar 31, 2022 | -17.53% |
| Dec 31, 2021 | -3.54% |
| Sep 30, 2021 | 14.49% |